Marco Pellicciaro

Dr. Marco Pellicciaro

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in In Vivo
Verified
Journal Article
Closed access
GVGianluca Vanni
Gianluca Vanni
MMMarco Materazzo
Marco Materazzo
MPMarco Pellicciaro
Marco Pellicciaro
SISara Ingallinella
Sara Ingallinella
MRMaurizio Rho
Maurizio Rho
OBOreste Claudio Buonomo
Oreste Claudio Buonomo
Background/Aim: Coronavirus-19 (COVID-19) pandemic outbreak is currently having a huge impact on medical resource allocation. Breast Cancer (BC) patients are concerned both with BC treatment and COVID-19. This study aimed to estimate the impact of anxiety among patients, caused by the spreading of COVID-19. Patients and Methods: Between the 16th of January and the 20th of March 2020, we retrospectively enrolled 160 patients. Eighty-two patients with a suspected breast lesion (SBL) were divided into two groups: PRE-COVID-19-SBL and POST-COVID-19-SBL. Seventy-eight BC patients were divided into PRE-COVID-19-BC and POST-COVID-19-BC. Patient characteristics including age, marital status, SBL/BC diameter, personal and family history of BC, clinical stage and molecular subtype were recorded. Procedure Refusal (PR) and Surgical Refusal (SR) were also recorded with their reason. Results: BC and SBL analysis showed no difference in pre-treatment characteristics (p>0.05). Both POST-COVID-19-SBL and POST-COVID-19-BC groups showed higher rates of PR and SR (p=0.0208, p=0.0065 respectively). Infection risk represented primary reason for refusal among POST-COVID-19 patients. Conclusion: COVID-19-related anxiety could affect patients’ decision-making process.

7 December 2020 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
GVGianluca Vanni
Gianluca Vanni
GTGiovanni Tazzioli
Giovanni Tazzioli
MPMarco Pellicciaro
Marco Pellicciaro
MMMarco Materazzo
Marco Materazzo
OPOrsaria Paolo
Orsaria Paolo
OBOreste Claudio Buonomo
Oreste Claudio Buonomo
Background/Aim: Extraordinary restrictions aimed to limit Sars-CoV-2 spreading; they imposed a total reorganization of the health-system. Oncological treatments experienced a significant slowdown. The aim of our multicentric retrospective study was to evaluate screening suspension and surgical treatment delay during COVID-19 and the impact on breast cancer presentation. Patients and Methods: All patients who underwent breast surgery from March 11, 2020 to May 30, 2020 were evaluated and considered as the Lockdown group. These patients were compared with similar patients of the previous year, the Pre-Lockdown group. Results: A total of 432 patients were evaluated; n=223 and n=209 in the Lockdown and Pre-lockdown-groups, respectively. At univariate analysis, waiting times, lymph-nodes involvement and cancer grading, showed a statistically significant difference (p<0.05). Multivariate analysis identified waiting-time on list (OR=1.07) as a statistically significant predictive factor of lymph node involvement. Conclusion: Although we did not observe a clinically evident difference in breast cancer presentation, we reported an increase in lymph node involvement.

31 August 2020 in In Vivo
Verified
Journal Article
Closed access
PDF file
GVGianluca Vanni
Gianluca Vanni
MPMarco Pellicciaro
Marco Pellicciaro
MMMarco Materazzo
Marco Materazzo
VBValentina Bruno
Valentina Bruno
COChiara Oldani
Chiara Oldani
OBOreste Claudio Buonomo
Oreste Claudio Buonomo
Background/Aim: Coronavirus disease is spreading worldwide. Due to fast transmission and high fatality rate drastic emergency restrictions were issued. During the lockdown, only urgent medical services are guaranteed. All non-urgent services, as breast cancer (BC) screening, are temporarily suspended. The potential of breast cancer screening programs in increasing the survival rate and decreasing the mortality rate has been widely confirmed. Suspension could lead to worse outcomes for breast cancer patients. Our study aimed to analyse the data and provide estimates regarding the temporary BC screening suspension. Patients and Methods: Data regarding breast cancer and respective screening programs were achieved through literature research and analysis. Results: Considering three different scenarios with respect to the lockdown's impact on breast cancer screening, we estimate that approximately 10,000 patients could have a missed diagnosis during these 3 months. Considering a 6-month period, as suggested by the Imperial college model, the number of patients who will not receive a diagnosis will rise to 16,000. Conclusion: Breast cancer screening should be resumed as soon as possible in order to avoid further breast cancer missed diagnosis and reduce the impact of delayed diagnosis.

1 June 2020 in In Vivo
Verified
Journal Article
Closed access
GVGianluca Vanni
Gianluca Vanni
MMMarco Materazzo
Marco Materazzo
FSFrancesca Santori
Francesca Santori
MPMarco Pellicciaro
Marco Pellicciaro
MCMaria Costesta
Maria Costesta
OBOreste Claudio Buonomo
Oreste Claudio Buonomo
Background/Aim: Despite the large amount of clinical data available of Coronavirus-19 (COVID-19), not many studies have been conducted about the psychological toll on Health Care Workers (HCWs). Patients and Methods: In this multicentric descriptive study, surveys were distributed among 4 different Breast Cancer Centers (BCC). BCCs were distinguished according to COVID-19 tertiary care hospital (COVID/No-COVID) and district prevalence (DP) (High vs. Low). DASS-21 score, PSS score and demographic data (age, sex, work) were evaluated. Results: A total of 51 HCWs were analyzed in the study. Age, work and sex did not demonstrate statistically significant values. Statistically significant distribution was found between DASS-21-stress score and COVID/No-COVID (p=0.043). No difference was found in the remaining DASS-21 and PSS scores, dividing the HCWs according to COVID-19-hospital and DP. Conclusion: Working in a COVID-19-hospital represents a factor that negatively affects psychosocial well-being. However, DP seems not to affect the psychosocial well-being of BCC HCWs. During the outbreak, psychological support for low risk HCWs should be provided regardless DP.

5 May 2021 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
GVGianluca Vanni
Gianluca Vanni
MPMarco Pellicciaro
Marco Pellicciaro
MMMarco Materazzo
Marco Materazzo
DPDomiziana Pedini
Domiziana Pedini
IPIlaria Portarena
Ilaria Portarena
OBOreste Claudio Buonomo
Oreste Claudio Buonomo
Background/Aim: The COVID-19 lockdown includes restrictive measures and temporary health system reorganization. Resources were shifted to COVID-19 patients, screening programs were temporary suspended, and oncological care suffered slow-down. The aim of the study was to evaluate the impact of these measures on breast cancer patients. Patients and Methods: All breast cancer patients referred to our unit from February 21, 2019 to February 21, 2021 were enrolled. Type of treatments and surgery, TNM, tumor diameter, and predictive and prognostic factors were analyzed. Results: Out of 445 patients with a breast cancer diagnosis, 182 (40.9%) were enrolled in the COVID-19 group (from February 21, 2010 to February 21, 2021). These patients were compared with 263 (59.1%) patients pre-COVID-19. Tumor diameters were bigger in the COVID-19 group. Type of surgery and N staging were statistically significantly different. Extreme advanced disease incidence was significantly different between the groups (2.7% COVID-19 group vs. 0 pre-COVID-19 group, p=0.011). Incidence of post-surgical radiation-therapy was higher in the COVID-19 group. Other variables analyzed were comparable without a statistically significant difference. Conclusion: COVID-19 led to increased tumor dimensions, advanced N-staging, and increased need for adjuvant treatments in breast cancer.

22 May 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GVgianluca vanni
gianluca vanni
MPMarco Pellicciaro
Marco Pellicciaro
MMMarco Materazzo
Marco Materazzo
LPLeonardo Palombi
Leonardo Palombi
OBOreste Claudio Buonomo
Oreste Claudio Buonomo
Breast Cancer Diagnosis in Coronavirus-Era: Alert From Italy